Related Experiment Video
Updated: Jan 7, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Accelerating recruitment in clinical trials: A strategic challenge
Dominique Deplanque1, Ariane Galaup2, Christine Trillou3
1University Lille, Inserm, CHU Lille, CIC 1403 - Centre d'investigation clinique, 59000 Lille, France.
Abstract:
Clinical research provides an important gateway to therapeutic innovation and, in many cases, national participation in trials can facilitate the future availability of new treatments in the country concerned. Clinical research activity in general is declining in France, especially in terms of industry-led trials; the only exception being early-phase cancer trials. There is an urgent need to boost the level of French participation in major international trials, although this will require a marked improvement in recruitment performance. Although the many factors contributing to the mediocre performance of France merit discussion, the overriding necessity is to bring forward solutions for increasing the level of participation in clinical trials going forward. It is against this background that we propose these recommendations for facilitating and increasing overall enrolment. There are a number of potential ways in which improvements could be achieved, beginning with identifying eligible patients and offering them the opportunity to take part in clinical trials, either through greater engagement by healthcare professionals or the development of decentralised trials. Other opportunities include optimising territorial coverage through inter-hospital networks or clinical trials centre networks, strengthening and improving clinical trials centre organisational structures by introducing AI-driven patient pre-screening tools, and lastly reprofiling some of the roles involved in clinical research and the provision of associated training. While some of these recommendations require regulatory changes, the majority could be implemented immediately, and would provide a rapid response to this major strategic challenge.
Insights
France needs to increase clinical trial participation to drive therapeutic innovation. Recommendations include better patient identification, decentralized trials, and AI tools to boost recruitment performance.
Area of Science:
- Clinical research and therapeutic innovation
- Healthcare policy and strategy
Background:
- Clinical research activity is declining in France, particularly industry-led trials, except for early-phase cancer studies.
- Low national participation in clinical trials hinders the future availability of new treatments.
- Improving recruitment performance is crucial for boosting French involvement in international trials.
Purpose of the Study:
- To propose actionable recommendations for facilitating and increasing overall patient enrollment in clinical trials in France.
- To address the strategic challenge of declining clinical research activity and enhance national participation.
Main Methods:
- Identifying eligible patients and increasing their opportunities to participate in clinical trials.
- Enhancing healthcare professional engagement and developing decentralized clinical trials.
- Optimizing territorial coverage via inter-hospital and clinical trial center networks.
- Implementing AI-driven patient pre-screening tools and strengthening organizational structures.
- Reprofiling roles and providing associated training for clinical research personnel.
Main Results:
- The proposed recommendations offer potential solutions to increase clinical trial participation.
- Many recommendations can be implemented immediately, requiring minimal regulatory changes.
- The strategies aim to provide a rapid response to the strategic challenge of low enrollment.
Conclusions:
- Boosting French participation in clinical trials is essential for therapeutic innovation.
- A multi-faceted approach involving healthcare professionals, technology, and organizational improvements is necessary.
- Immediate implementation of proposed strategies can significantly enhance clinical trial enrollment and address a major strategic challenge.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:28Preclinical Development: Overview
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:26Drug Discovery: Overview
01:11Blinding